Study Summary
The goal of this clinical trial is to evaluate the safety and efficacy of anti-ALPP chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with ALPP-positive Advanced Solid Tumors.
Want to learn more about this trial?
Request More InfoInterventions
Retroviral vector-transduced autologous T cells to express anti-ALPP CARsDRUG
Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Department of Oncology, Xinqiao Hospital | Chongqing | Chongqing Municipality | China |